Gilead Sciences, Inc. (GILD)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 66.95 |
| Open | 67.09 |
| Bid | 66.97 x 500 |
| Ask | 67.04 x 400 |
| Day's range | 67.00 - 67.68 |
| 52-week range | 65.90 - 87.87 |
| Volume | |
| Avg. volume | 7,228,700 |
| Market cap | 83.584B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 14.90 |
| EPS (TTM) | 4.50 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | 3.08 (4.60%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | 78.70 |
ZacksIncyte (INCY) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksGilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
ZacksInsights Into Gilead (GILD) Q1: Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Gilead (GILD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
© 2024 Yahoo. All rights reserved.